应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
TEVA 梯瓦制药
交易中 12-26 15:31:42 EST
31.78
+0.04
+0.13%
最高
31.89
最低
31.47
成交量
173.13万
今开
31.50
昨收
31.74
日振幅
1.31%
总市值
364.61亿
流通市值
362.78亿
总股本
11.47亿
成交额
5,501万
换手率
0.15%
流通股本
11.42亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
小摩上调梯瓦制药目标价至35美元
格隆汇 · 12-17
小摩上调梯瓦制药目标价至35美元
梯瓦制药推出Rise：全球开放创新平台以加速AI、工业4.0、智能制造、数字健康和生物科技突破，解决制药行业的重大挑战
美股速递 · 11-19
梯瓦制药推出Rise：全球开放创新平台以加速AI、工业4.0、智能制造、数字健康和生物科技突破，解决制药行业的重大挑战
财报绩优股强劲拉升，Digital Turbine暴涨超38%
老虎资讯综合 · 11-05
财报绩优股强劲拉升，Digital Turbine暴涨超38%
异动解读 | 业绩超预期且上调全年展望，梯瓦制药盘中大涨15.52%
异动解读 · 11-05
异动解读 | 业绩超预期且上调全年展望，梯瓦制药盘中大涨15.52%
美股异动 | 梯瓦制药(TEVA.US)盘前大涨近13% Q3营收和调整后每股收益均超预期
智通财经 · 11-05
美股异动 | 梯瓦制药(TEVA.US)盘前大涨近13% Q3营收和调整后每股收益均超预期
异动解读 | 梯瓦制药盘前大涨近12%，三季度业绩超预期且上调全年展望
异动解读 · 11-05
异动解读 | 梯瓦制药盘前大涨近12%，三季度业绩超预期且上调全年展望
梯瓦制药三季度每股收益、净收入均高于预期，上调全年每股收益展望
老虎资讯综合 · 11-05
梯瓦制药三季度每股收益、净收入均高于预期，上调全年每股收益展望
梯瓦制药召回超58万瓶盐酸哌唑嗪
环球市场播报 · 10-31
梯瓦制药召回超58万瓶盐酸哌唑嗪
美国FDA批准梯瓦制药的肥胖症仿制药
格隆汇 · 08-28
美国FDA批准梯瓦制药的肥胖症仿制药
FDA批准Ajovy（fremanezumab-vfrm）扩大适应症，这是首个用于儿童阵发性偏头痛预防的抗CGRP治疗药物FDA Approves Expanded Indication for Ajovy (fremanezumab-vfrm), the First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine
动脉网 · 08-07
FDA批准Ajovy（fremanezumab-vfrm）扩大适应症，这是首个用于儿童阵发性偏头痛预防的抗CGRP治疗药物FDA Approves Expanded Indication for Ajovy (fremanezumab-vfrm), the First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine
异动解读 | 梯瓦制药盘中大跌5%，尽管财报显示业绩改善
异动解读 · 08-01
异动解读 | 梯瓦制药盘中大跌5%，尽管财报显示业绩改善
梯瓦制药(TEVA)盘前涨3.14% 第二财季扭亏为盈
金吾财讯 · 07-30
梯瓦制药(TEVA)盘前涨3.14% 第二财季扭亏为盈
盘点 | 2025年上半年生物制药行业裁员TOP5
Ofweek光电信息网 · 07-13
盘点 | 2025年上半年生物制药行业裁员TOP5
梯瓦制药盘中异动 急速下跌5.01%
市场透视 · 03-10
梯瓦制药盘中异动 急速下跌5.01%
B of A Securities：维持Teva Pharmaceutical Indus(TEVA.US)评级，由买入调整至买入评级, 目标价由23.00美元调整至20.00美元。
金融界 · 03-06
B of A Securities：维持Teva Pharmaceutical Indus(TEVA.US)评级，由买入调整至买入评级, 目标价由23.00美元调整至20.00美元。
赛诺菲(SNY.US)与梯瓦(TEVA.US)共同开发的duvakitug预计在下半年启动3期临床试验
智通财经 · 02-25
赛诺菲(SNY.US)与梯瓦(TEVA.US)共同开发的duvakitug预计在下半年启动3期临床试验
梯瓦制药盘中异动 股价大涨5.01%报17.40美元
市场透视 · 02-20
梯瓦制药盘中异动 股价大涨5.01%报17.40美元
梯瓦制药盘中异动 早盘股价大涨5.15%报17.09美元
市场透视 · 02-18
梯瓦制药盘中异动 早盘股价大涨5.15%报17.09美元
梯瓦制药2024财年实现净利润-16.39亿美元，同比减少193.20%
市场透视 · 02-07
梯瓦制药2024财年实现净利润-16.39亿美元，同比减少193.20%
加载更多
公司概况
公司名称：
梯瓦制药
所属市场：
NYSE
上市日期：
--
主营业务：
Teva Pharmaceutical Industries Limited于1944年2月13日在以色列注册成立。该公司是一家全球性制药公司，致力于帮助世界各地的患者获得负担得起的药物，并从改善健康的创新中受益。该公司的使命是成为仿制药、创新药和生物制药领域的全球领导者，改善患者的生活。该公司在全球开展业务，总部设在以色列，并在美国、欧洲和世界各地的许多其他市场都有重要业务。
发行价格：
--
{"stockData":{"symbol":"TEVA","market":"US","secType":"STK","nameCN":"梯瓦制药","latestPrice":31.78,"timestamp":1766781102002,"preClose":31.74,"halted":0,"volume":1731273,"delay":0,"floatShares":1141527812,"shares":1147282512,"eps":0.617121,"marketStatus":"交易中","change":0.04,"latestTime":"12-26 15:31:42 EST","open":31.5,"high":31.885,"low":31.47,"amount":55014726.178101,"amplitude":0.013075,"askPrice":31.79,"askSize":755,"bidPrice":31.78,"bidSize":3565,"shortable":3,"etf":0,"ttmEps":0.617121,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1766782800000},"marketStatusCode":2,"adr":0,"adrRate":1,"exchange":"NYSE","adjPreClose":31.74,"preHourTrading":{"tag":"盘前","latestPrice":31.7599,"preClose":31.74,"latestTime":"09:29 EST","volume":10683,"amount":339577.74342,"timestamp":1766759372554},"postHourTrading":{"tag":"盘后","latestPrice":31.84,"preClose":31.74,"latestTime":"16:48 EST","volume":621094,"amount":19713589.5961,"timestamp":1766612938732},"volumeRatio":0.199257,"impliedVol":0.382,"impliedVolPercentile":0.316},"requestUrl":"/m/hq/s/TEVA","defaultTab":"news","newsList":[{"id":"2592915962","title":"小摩上调梯瓦制药目标价至35美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2592915962","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592915962?lang=zh_cn&edition=full","pubTime":"2025-12-17 15:28","pubTimestamp":1765956515,"startTime":"0","endTime":"0","summary":"摩根大通将梯瓦制药的目标价从28美元上调至35美元，维持“增持”评级。\n\n美股频道更多独家策划、专家专栏，免费查阅>>\n\r\n 责任编辑：山上","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2025/12/17152854717110.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["TEVA"],"gpt_icon":0},{"id":"1111678277","title":"梯瓦制药推出Rise：全球开放创新平台以加速AI、工业4.0、智能制造、数字健康和生物科技突破，解决制药行业的重大挑战","url":"https://stock-news.laohu8.com/highlight/detail?id=1111678277","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111678277?lang=zh_cn&edition=full","pubTime":"2025-11-19 21:01","pubTimestamp":1763557279,"startTime":"0","endTime":"0","summary":"梯瓦制药推出Rise：全球开放创新平台以加速AI、工业4.0、智能制造、数字健康和生物科技突破，解决制药行业的重大挑战。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4559","BK4585","TEVA","LU1983299246.USD","BK4007","BK4596","BK4566","BK4584","BK4557"],"gpt_icon":0},{"id":"1186868393","title":"财报绩优股强劲拉升，Digital Turbine暴涨超38%","url":"https://stock-news.laohu8.com/highlight/detail?id=1186868393","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186868393?lang=zh_cn&edition=full","pubTime":"2025-11-05 23:23","pubTimestamp":1762356194,"startTime":"0","endTime":"0","summary":"Lumentum Holdings Inc.涨超20%。","market":"us","thumbnail":"https://static.tigerbbs.com/591f197978533795137daedf87e7f110","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/591f197978533795137daedf87e7f110"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DOCN","APPS","TEVA","RIVN","LITE"],"gpt_icon":0},{"id":"1156177265","title":"异动解读 | 业绩超预期且上调全年展望，梯瓦制药盘中大涨15.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=1156177265","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156177265?lang=zh_cn&edition=full","pubTime":"2025-11-05 23:21","pubTimestamp":1762356076,"startTime":"0","endTime":"0","summary":"周三盘中，梯瓦制药股价大幅攀升，涨幅高达15.52%，引发市场广泛关注。这一显著涨幅主要源于公司发布的亮眼第三季度财报以及上调的全年业绩指引。除了强劲的季度业绩外，梯瓦制药还上调了2025年全年业绩展望，进一步提振了投资者信心。公司将全年非GAAP每股收益预期区间上调至2.55美元至2.65美元，高于此前2.50美元至2.65美元的预期。市场对梯瓦制药的积极表现反应热烈，导致其股价在盘中大幅上涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"9d90d278b477e225f212630fc0d7adfc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["TEVA"],"gpt_icon":0},{"id":"2581773230","title":"美股异动 | 梯瓦制药(TEVA.US)盘前大涨近13% Q3营收和调整后每股收益均超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2581773230","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581773230?lang=zh_cn&edition=full","pubTime":"2025-11-05 21:59","pubTimestamp":1762351188,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周三，梯瓦制药(TEVA.US)盘前大涨近13%，报23.10美元。梯瓦制药Q3营收为44.8亿美元，市场预期为43.4亿美元；调整后每股收益0.78美元，市场预期为0.68美元。公司预计2025财年全年收入区间为168亿美元至170亿美元，而FactSet的预估为168.3亿美元。公司将2025财年调整后每股收益指引从2.50-2.60美元上调至2.55-2.65美元，分析师预期为2.58美元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":"0e10452748c8c56d37b9e4059781f9d7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1365746.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"美股异动 | 梯瓦制药(TEVA.US)盘前大涨近13% Q3营收和调整后每股收益均超预期","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["TEVA"],"gpt_icon":0},{"id":"1117966103","title":"异动解读 | 梯瓦制药盘前大涨近12%，三季度业绩超预期且上调全年展望","url":"https://stock-news.laohu8.com/highlight/detail?id=1117966103","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117966103?lang=zh_cn&edition=full","pubTime":"2025-11-05 21:37","pubTimestamp":1762349847,"startTime":"0","endTime":"0","summary":"11月5日周三盘前，制药巨头梯瓦制药股价大幅攀升，涨幅高达11.97%，引发市场广泛关注。这一显著涨幅主要源于公司发布的亮眼第三季度财报以及上调的全年业绩指引。根据梯瓦制药最新发布的财务报告，公司第三季度表现出色，多项关键指标均超出市场预期。除了强劲的季度业绩外，梯瓦制药还上调了2025年全年业绩展望，进一步提振了投资者信心。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"9d90d278b477e225f212630fc0d7adfc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["TEVA"],"gpt_icon":0},{"id":"1125594271","title":"梯瓦制药三季度每股收益、净收入均高于预期，上调全年每股收益展望","url":"https://stock-news.laohu8.com/highlight/detail?id=1125594271","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125594271?lang=zh_cn&edition=full","pubTime":"2025-11-05 21:33","pubTimestamp":1762349608,"startTime":"0","endTime":"0","summary":"$梯瓦制药(TEVA)$ 第三季度非GAAP每股收益为0.78美元，高于去年同期的0.69美元。分析师此前预期为0.68美元。截至9月30日的季度净收入为44.8亿美元，高于去年同期的43.3亿美元。分析师此前预期为43.4亿美元。公司目前预计2025年非GAAP每股收益为2.55美元至2.65美元，高于此前预期的2.50美元至2.65美元。分析师此前预期为2.57美元。预计本年度营收为168亿美元至170亿美元，与此前预期的168亿美元至172亿美元基本持平。分析师此前预期为168.3亿美元。梯瓦制药盘前拉升大涨近12%。","market":"us","thumbnail":"https://static.tigerbbs.com/78d9ba8187b842ab8acf01c54743285d","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/78d9ba8187b842ab8acf01c54743285d"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":"9d90d278b477e225f212630fc0d7adfc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TEVA"],"gpt_icon":0},{"id":"2579498458","title":"梯瓦制药召回超58万瓶盐酸哌唑嗪","url":"https://stock-news.laohu8.com/highlight/detail?id=2579498458","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579498458?lang=zh_cn&edition=full","pubTime":"2025-10-31 22:19","pubTimestamp":1761920340,"startTime":"0","endTime":"0","summary":"梯瓦制药（Teva Pharmaceutical Industries，TEVA）上涨0.7%。美国FDA提示亚硝胺污染风险后，梯瓦制药自愿召回超58万瓶盐酸哌唑嗪，本次召回属II类风险。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-10-31/doc-infvvcyr4247885.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4007","BK4559","TEVA","LU1983299246.USD","BK4596","BK4584","BK4566","BK4585","BK4588","BK4557"],"gpt_icon":0},{"id":"2562403716","title":"美国FDA批准梯瓦制药的肥胖症仿制药","url":"https://stock-news.laohu8.com/highlight/detail?id=2562403716","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562403716?lang=zh_cn&edition=full","pubTime":"2025-08-28 20:58","pubTimestamp":1756385890,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE00BZ1G4Q59.USD","BK4532","BK4007","LU0154236417.USD","BK4566","BK4584","BK4559","BK4585","IE00BKVL7J92.USD","LU1093756325.SGD","NVO","TEVA","BK4588","BK4557","BK4596","LU1093756168.USD","BK4599"],"gpt_icon":0},{"id":"2557580919","title":"FDA批准Ajovy（fremanezumab-vfrm）扩大适应症，这是首个用于儿童阵发性偏头痛预防的抗CGRP治疗药物FDA Approves Expanded Indication for Ajovy (fremanezumab-vfrm), the First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine","url":"https://stock-news.laohu8.com/highlight/detail?id=2557580919","media":"动脉网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557580919?lang=zh_cn&edition=full","pubTime":"2025-08-07 10:32","pubTimestamp":1754533920,"startTime":"0","endTime":"0","summary":"通过此项批准，Ajovy成为首个且唯一用于预防性治疗儿科患者偶发性偏头痛和成人偏头痛的降钙素基因相关肽拮抗剂，标志着在扩大偏头痛患者预防性治疗选择方面取得了重要的进展。Ajovy每月注射一次，可在诊所或家中使用，提供了一种旨在支持依从性并减轻家庭治疗负担的治疗选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080710331794d4a3c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080710331794d4a3c2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4559","BK4585","TEVA","BK4007","BK4596","BK4566","BK4584","BK4557"],"gpt_icon":0},{"id":"1114560272","title":"异动解读 | 梯瓦制药盘中大跌5%，尽管财报显示业绩改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1114560272","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114560272?lang=zh_cn&edition=full","pubTime":"2025-08-01 00:02","pubTimestamp":1753977762,"startTime":"0","endTime":"0","summary":"梯瓦制药今日盘中股价大跌5.05%，尽管公司最新发布的财报显示业绩有所改善。这一反差引发了市场的广泛关注。根据梯瓦制药发布的2025财年第二季度财报，公司前六个月累计营收为80.67亿美元，同比小幅增长1.05%。尽管财务数据显示公司经营状况有所好转，但投资者似乎对这一改善并不满意。分析人士指出，这可能是由于市场对梯瓦制药的期望更高，或者存在其他影响投资者信心的因素。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["TEVA"],"gpt_icon":0},{"id":"2555448540","title":"梯瓦制药(TEVA)盘前涨3.14% 第二财季扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2555448540","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555448540?lang=zh_cn&edition=full","pubTime":"2025-07-30 20:41","pubTimestamp":1753879280,"startTime":"0","endTime":"0","summary":"金吾财讯 | 梯瓦制药 盘前涨3.14%，报17.06美元。消息面上，公司公布第二季度业绩，利润为2.82亿美元，而去年同期亏损8.46亿美元。经调整每股收益为0.66美元，超出市场预期的0.63美元。期内营收42亿美元，与去年同期相比基本持平，但略低于市场预期的42.8亿美元。公司的转型计划有望到2027年实现约7亿美元的净节省，预计2025年将实现约7000万美元。公司仍专注于到2027年实现30%的营业利润率目标。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250107/N2NlYWIzMDQ5MjY5YzU0NWM0NDMwZTE4ZDQ3MjY3ODIxNTA5MDg=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/N2NlYWIzMDQ5MjY5YzU0NWM0NDMwZTE4ZDQ3MjY3ODIxNTA5MDg=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"290964","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4557","BK4559","BK4566","TEVA","BK4007","BK4584","BK4596"],"gpt_icon":0},{"id":"2551391778","title":"盘点 | 2025年上半年生物制药行业裁员TOP5","url":"https://stock-news.laohu8.com/highlight/detail?id=2551391778","media":"Ofweek光电信息网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551391778?lang=zh_cn&edition=full","pubTime":"2025-07-13 10:13","pubTimestamp":1752372780,"startTime":"0","endTime":"0","summary":"2025年上半年，生物制药行业裁员企业和人数均同比大幅增加。据BioSpace统计，今年上半年，共有130家生物制药企业实施裁员，累计裁减员工达到13,470人，较2024年同期91家公司裁减的10,276名员工增长31%。本文特别盘点了2025年上半年规模最大的五轮生物制药行业裁员事件，涵盖行业巨头拜耳、百时美施贵宝和梯瓦制药等知名企业。自2023年7月启动大规模重组以来，拜耳已累计裁员约1.1万人。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250713102220954074ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250713102220954074ae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4557","BK4585","BK4559","TEVA","BK4566","BK4596","BK4007","BK4588","BMS","BK4584"],"gpt_icon":0},{"id":"2518274873","title":"梯瓦制药盘中异动 急速下跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518274873","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518274873?lang=zh_cn&edition=full","pubTime":"2025-03-10 23:09","pubTimestamp":1741619345,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日23时09分，梯瓦制药股票出现波动，股价急速跳水5.01%。梯瓦制药股票所在的制药行业中，整体跌幅为1.97%。梯瓦制药公司简介：梯瓦制药工业有限公司总部位于以色列，是世界领先的仿制药制造商。梯瓦一半的销售额来自北美，在美国仿制药处方总数中所占的比例很高，为个位数。梯瓦还销售活性药物成分，提供合同制造服务，并拥有美国仿制药和特种药分销商Anda。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310230905abf32054&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310230905abf32054&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4566","BK4584","TEVA","BK4007","BK4596","BK4557","BK4559","BK4588","BK4585"],"gpt_icon":0},{"id":"2517216414","title":"B of A Securities：维持Teva Pharmaceutical Indus(TEVA.US)评级，由买入调整至买入评级, 目标价由23.00美元调整至20.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517216414","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517216414?lang=zh_cn&edition=full","pubTime":"2025-03-06 23:46","pubTimestamp":1741275975,"startTime":"0","endTime":"0","summary":"B of A Securities：维持Teva Pharmaceutical Indus(TEVA.US)评级，由买入调整至买入评级, 目标价由23.00美元调整至20.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/06234648576704.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["TEVA"],"gpt_icon":0},{"id":"2514803042","title":"赛诺菲(SNY.US)与梯瓦(TEVA.US)共同开发的duvakitug预计在下半年启动3期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2514803042","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514803042?lang=zh_cn&edition=full","pubTime":"2025-02-25 14:33","pubTimestamp":1740465193,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，赛诺菲与梯瓦日前公布了其共同开发的在研单抗duvakitug在2b期临床试验RELIEVE UCCD中获得的详细结果。新闻稿表示，这一结果展现了duvakitug成为“best-in-class”疗法的潜力。两家公司预计在今年下半年启动3期临床试验。2b期临床试验数据显示，接受duvakitug治疗的UC患者中，36%的低剂量组和48%高剂量组患者实现临床缓解，此数值在安慰剂组仅为20%。靶向TL1A有望缓解IBD患者的过度免疫反应。赛诺菲与梯瓦在2023年达成合作，共同开发并商业化duvakitug，用于治疗UC和CD。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1253916.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK4584","IE00BFXG1179.USD","BK1576","BK4588","BK4557","SNY","TEVA","BK4566","03347","BK1141","BK4596","BK4585","BK4559","BK4007"],"gpt_icon":0},{"id":"2512481529","title":"梯瓦制药盘中异动 股价大涨5.01%报17.40美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512481529","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512481529?lang=zh_cn&edition=full","pubTime":"2025-02-20 00:04","pubTimestamp":1739981061,"startTime":"0","endTime":"0","summary":"北京时间2025年02月20日00时04分，梯瓦制药股票出现波动，股价大幅拉升5.01%。截至发稿，该股报17.40美元/股，成交量390.546万股，换手率0.34%，振幅4.53%。最近的财报数据显示，该股实现营业收入165.10亿美元，净利润-16.39亿美元，每股收益-1.45美元，毛利80.29亿美元，市盈率-11.97倍。梯瓦制药股票所在的制药行业中，整体涨幅为1.34%。梯瓦还销售活性药物成分，提供合同制造服务，并拥有美国仿制药和特种药分销商Anda。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220000421abd511a0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220000421abd511a0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4557","BK4007","BK4588","BK4596","TEVA","BK4559","BK4585","BK4584","BK4566"],"gpt_icon":1},{"id":"2512165019","title":"梯瓦制药盘中异动 早盘股价大涨5.15%报17.09美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512165019","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512165019?lang=zh_cn&edition=full","pubTime":"2025-02-18 22:32","pubTimestamp":1739889124,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日22时32分，梯瓦制药股票出现异动，股价快速拉升5.15%。截至发稿，该股报17.09美元/股，成交量84.8608万股，换手率0.07%，振幅0.49%。梯瓦制药股票所在的制药行业中，整体涨幅为0.82%。梯瓦一半的销售额来自北美，在美国仿制药处方总数中所占的比例很高，为个位数。梯瓦还销售活性药物成分，提供合同制造服务，并拥有美国仿制药和特种药分销商Anda。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218223204a24aacac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218223204a24aacac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4559","BK4585","TEVA","BK4007","BK4596","BK4566","BK4584","BK4557"],"gpt_icon":0},{"id":"2509873255","title":"梯瓦制药2024财年实现净利润-16.39亿美元，同比减少193.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509873255","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509873255?lang=zh_cn&edition=full","pubTime":"2025-02-07 09:00","pubTimestamp":1738890018,"startTime":"0","endTime":"0","summary":"2月7日，梯瓦制药公布财报，公告显示公司2024财年净利润为-16.39亿美元，同比减少193.20%；其中营业收入为165.10亿美元，同比增加4.18%，每股基本收益为-1.45美元。从资产负债表来看，梯瓦制药总负债336.06亿美元，其中短期债务18.68亿美元，资产负债比为1.18，流动比率为0.99。机构评级：截至2025年2月7日，当前有7家机构对梯瓦制药目标价做出预测，其中目标均价为24.71美元，其中最低目标价为21.00美元，最高目标价为30.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207090020abc5596e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207090020abc5596e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TEVA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tevapharm.com","stockEarnings":[{"period":"1week","weight":0.0559},{"period":"1month","weight":0.2814},{"period":"3month","weight":0.7288},{"period":"6month","weight":0.8938},{"period":"1year","weight":0.4157},{"period":"ytd","weight":0.4401}],"compareEarnings":[{"period":"1week","weight":0.0283},{"period":"1month","weight":0.0324},{"period":"3month","weight":0.0491},{"period":"6month","weight":0.1227},{"period":"1year","weight":0.1481},{"period":"ytd","weight":0.178}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Teva Pharmaceutical Industries Limited于1944年2月13日在以色列注册成立。该公司是一家全球性制药公司，致力于帮助世界各地的患者获得负担得起的药物，并从改善健康的创新中受益。该公司的使命是成为仿制药、创新药和生物制药领域的全球领导者，改善患者的生活。该公司在全球开展业务，总部设在以色列，并在美国、欧洲和世界各地的许多其他市场都有重要业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.692308,"avgChangeRate":0.061256},{"month":2,"riseRate":0.384615,"avgChangeRate":-0.018156},{"month":3,"riseRate":0.461538,"avgChangeRate":-0.012141},{"month":4,"riseRate":0.307692,"avgChangeRate":-0.005695},{"month":5,"riseRate":0.461538,"avgChangeRate":-0.006181},{"month":6,"riseRate":0.5,"avgChangeRate":0.012853},{"month":7,"riseRate":0.571429,"avgChangeRate":0.027357},{"month":8,"riseRate":0.214286,"avgChangeRate":-0.047364},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.0119},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.019229},{"month":11,"riseRate":0.642857,"avgChangeRate":0.061945},{"month":12,"riseRate":0.571429,"avgChangeRate":0.031442}],"exchange":"NYSE","name":"梯瓦制药","nameEN":"Teva Pharmaceutical"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"梯瓦制药(TEVA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供梯瓦制药(TEVA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"梯瓦制药,TEVA,梯瓦制药股票,梯瓦制药股票老虎,梯瓦制药股票老虎国际,梯瓦制药行情,梯瓦制药股票行情,梯瓦制药股价,梯瓦制药股市,梯瓦制药股票价格,梯瓦制药股票交易,梯瓦制药股票购买,梯瓦制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"梯瓦制药(TEVA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供梯瓦制药(TEVA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}